On February 20, 2019, document Shen Shi Jian [2019] No. 41 issued by the Shenzhen Market Supervision Administration recognized Shenzhen Beike Biotechnology Co., Ltd. (hereinafter "Beike Biotech") as a "Demonstration Enterprise for Synchronized R&D and Standardization."
This honor reflects the recognition by various municipal departments of Beike Biotech's work on R&D and standardization, marking a new step forward by Beike Biotech, a leader in the cell technology industry, in advancing industry standardization!
The "Demonstration Enterprise for Synchronized R&D and Standardization" review, started in 2017, has now been carried out for two consecutive years. It was established under the Shenzhen Municipal Government's "Shenzhen Standard International Innovation City Demonstration Initiative Plan" and the standard requirements of the "Evaluation Guide for Demonstration Enterprises in Synchronized R&D and Standardization," and is an important part of building "Shenzhen Quality" and "Shenzhen Standards." The aim is to assess the effectiveness of synchronized R&D and standardization, identify and recognize a group of demonstration enterprises, and harness the demonstration and leading effect of benchmark enterprises.
Cell preparation technology is a complex high-tech field, and standardization is relatively underdeveloped. As a trailblazer in this field, Beike Biotech has long been committed to industry standardization:
In 2011, Beike Biotech overcame major hurdles and was the first to introduce international AABB accreditation;
In 2016, Beike Biotech took the lead in drafting Shenzhen local standards "Specification for the Construction and Management of Cell Preparation Centers" and "Specification for the Establishment and Management of Comprehensive Cell Banks";
In 2016, Beike Biotech participated in formulating the "Self-Regulatory Specification for Quality Management of Stem Cell Preparation" and the "Self-Regulatory Specification for Quality Management of Immune Cell Preparation";
In 2018, Beike Biotech was the first to apply to the Human Resources and Social Security Bureau for the "Cell Preparation Engineer" professional title;
In 2018, Beike Biotech was the first to introduce third-party quality testing.
......
Beike Biotech is among the earliest National High-Tech Enterprises in China specializing in the clinical translation and technology services of biotherapy technology, a strategic emerging industry. We attach great importance to R&D and standardization management, and we drive and safeguard the synchronized development of technology R&D, standards innovation and industrialization through organizational structure, budget, and management systems.
This time, after self-evaluation, application, oral defense, expert review, and public announcement, Beike Biotech smoothly earned the title of "Demonstration Enterprise for Synchronized R&D and Standardization." This is a vote of confidence from the municipal government and society in Beike Biotech's standardization and R&D work!
As a trailblazer in this field, Beike Biotech will continue to invest in R&D and standardization, drive more efficient corporate development, deliver better services to users, and contribute even more to the standardization efforts of the country and the industry!
